Drugs / MDR-103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03606746 | Dec 2024 → Aug 2025 | transplant rejection | Medeor Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDR-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03606746 ↗ |
| Modality | Cell therapy | “novel cell-based therapy” NCT03606746 ↗ |
| Route | Intravenous | “single IV infusion of MDR-103” NCT03606746 ↗ |